Distinguishing Participant Groups Using Autonomic Dysfunction
NCT ID: NCT05199350
Last Updated: 2023-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
175 participants
OBSERVATIONAL
2021-11-17
2022-07-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Distinguishing Patient Groups Using Autonomic Dysfunction
NCT04964921
Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes
NCT01409239
Monitoring Exhaled Breath to Noninvasively Detect Glycemic Events
NCT06893341
Use of iPro™2 in Real Life Diabetes Management of Type 2 Patients in India
NCT01995539
Continuous Glucose Monitoring for Various Degrees of Glucose Intolerance
NCT05491954
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is no gold standard for measuring autonomic dysfunction. Currently the method of power spectral analysis is finding very wide usage. It Is known that power spectral analysis does not discriminate the two subsystems of the ANS well. There are other beat to beat methodologies that have not yet gained traction. The reason for conducting this trial is to take a group of subjects in various stages of impaired fasting glucose, impaired glucose tolerance and diabetes (with and without complications) and determine which methodology stratifies these subjects most accurately.
Our study aims to introduce a new measurement method named the 'Beat to Beat' (BB) method for gauging autonomic dysfunction in patients. The investigators hope to observe that the average beat to beat method (BB) score could help discriminating diabetic patients into the following five distinct groups from the pilot study:
1. Normal Glucose Tolerance (NGT) is defined as a plasma glucose concentration i.e \< 140 mg/dl.
2. Impaired Fasting Glucose (IFG) is defined by an elevated fasting plasma glucose (FPG) concentration i.e ≥ 100 and \< 126 mg/dl.
3. Impaired Glucose Tolerance (IGT) is defined by an elevated post-prandial plasma glucose concentration i.e ≥140 and \< 200 mg/dl.
4. Presence of confirmed diabetes (HbA1c level \> 6.4 %) without complications i.e no neuropathy, no retinopathy, no nephropathy etc.
5. Presence of confirmed diabetes (HbA1c level \> 6.4 %) with at least one of the above complications.
By showing that this measurement bears no relationship to the other four vital signs parameters (heart rate, blood oxygenation, blood pressure, body temperature), it will prove the necessity of this measurement in addition to the four vital signs for distinguishing patient groups among the diabetic population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Population including people with NGT, IFG and IGT and diabetes.
Normal Glucose Tolerance (NGT) is defined as a plasma glucose concentration i.e \< 140 mg/dl.
IFG is defined by an elevated fasting plasma glucose (FPG) concentration i.e ≥ 100 and \< 126 mg/dl.
IGT is defined by an elevated post-prandial plasma glucose concentration i.e ≥140 and \< 200 mg/dl.
Presence of confirmed diabetes (HbA1c level \> 6.4 %) without complications i.e no neuropathy, no retinopathy, no nephropathy etc.
Presence of confirmed diabetes (HbA1c level \> 6.4 %) with at least one of the above complications.
Device Name: ANSiscope
Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Device Name: ANSiscope
Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age between 18 to 85
3. Body Mass Index (BMI) between 25 and 40 kg/m2
4. Individuals with normal glucose levels, pre-diabetes and diabetes Type 2 for at least 1 year (diagnosed by ADA criteria) and up to 20 years
5. Stable dose of meds for 3 months
6. Stable diet and lifestyle for 3 months
7. Medical history without clinically significant abnormalities
Exclusion Criteria
2. Chronic disease (e.g. HIV, Cushing syndrome, CKD, acromegaly, active hyperthyroidism etc.)
3. Cancer and anticancer treatment in the last 5 years
4. Pregnancy or lactation
5. Subjects with major physical disability
6. Subjects with previous history of cerebrovascular accident
7. Any disorder, which in the investigator's opinion might jeo
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DyAnsys, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dr. Mathangi Dr D.C, Prof &Head M.SC., Phd
Role: PRINCIPAL_INVESTIGATOR
Sri Rachandra Institute of HigherEducation And Research hospital
priscilla Dr johnson, MBBS,MD, DNB, PhD
Role: STUDY_CHAIR
Sri Rachandra Institute of HigherEducation And Research hospital
shriram Dr Mahadevan
Role: PRINCIPAL_INVESTIGATOR
Sri Rachandra Institute of HigherEducation And Research hospital
Divyalakshmi Dr Divyalakshmi k, MBBS,MD
Role: STUDY_DIRECTOR
Sri Rachandra Institute of HigherEducation And Research hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sri Rachandra Institute of HigherEducation And Research
Chennai, Tamil Nadu, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.